SEC Form SC 13D/A filed by Shattuck Labs Inc. (Amendment)

12/8/22 8:40:53 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $STTK alert in real time by email

SC 13D/A 1 josiah13dsttk.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment #1) SHATTUCK LABS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 820824L103 (CUSIP Number) ERIN ATOR THOMSON GENERAL COUNSEL SHATTUCK LABS, INC. 500 W 5TH STREET, SUITE 1200 AUSTIN, TX 78701 (512) 900-4690 (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications) AS OF DECEMBER 08, 2022 (Date of Event Which Required Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Section 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box. [ ] The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of seurities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 820824L103 13D 1. Names of Reporting Persons, I.R.S. Identification Nos. of above persons (entities only): JOSIAH HORNBLOWER 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] 3. SEC Use Only 4. Source of Fund (See Instructions) PF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ] 6. Citizenship or Place of Organization UNITED STATES Number of 7. Sole Voting Power: 2,977,627 Shares Bene- ficially Owned by Each 8. Shared Voting Power: 0 Reporting Person With: 9. Sole Dispositive Power: 2,977,627 10. Shared Dispositive Power: 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person: 2,977,627 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] 13. Percent of Class Represented by Amount in Row (11): 7.0% (1) 14. Type of Reporting Person (See Instructions) IN (1) Based on 42,386,470 shares of Common Stock issued and outstanding upon the closing of the Issuer's most recent 10-Q filing dated September 30, 2022. CUSIP No. 820824L103 13D ITEM 1. Security and Issuer: This statement on Schedule 13D (this "Statement") is filed with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Shattuck Labs, Inc. a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 500 W 5th Street, Suite 1200, Austin, TX 78701. ITEM 2. Identity and Background (a) This statement is filed on behalf of Josiah Hornblower (the "Reporting Person"). As of the date of this Statement, Mr. Hornblower beneficially owns 2,977,627 shares of Common Stock and is the direct owner of 85,774 shares of Common Stock, of which 188,375 shares of Common Stock were from exercised stock options in June 2021. Mr. Hornblower transferred 20,000 shares of Common Stock to a charitable giving account in February 2021 and 70,000 shares of Common Stock to family members in December 2021. Additionally, 79,356 shares of Common Stock were previously held by Stone Dock Investors. In September 2021, Stone Dock distributed 12,399 shares of Common Stock to Mr. Hornblower and 66,957 shares of Common Stock to other investors in Stone Dock. Mr. Hornblower is the beneficial owner of 2,891,853 shares of Common Stock held by Hornblower Capital Holdings, LLC. Hornblower Capital Holdings, LLC and Stone Dock Investors are controlled by Mr. Hornblower; however, Mr. Hornblower did not control the charitable giving account. (b) The business address of the Reporting Person is 3317 Bowman Avenue Austin, TX 78703. (c) The principal occupation of Mr. Hornblower is investment manager. Mr. Hornblower was previously Executive Chairman and director of the Issuer. (d) & (e) During the last five years, the Reporting Person has not (i) been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws of finding any violation with respect to such laws. (f) Mr. Hornblower is a citizen of the United States of America. ITEM 3. Source and Amount of Funds or Other Consideration The Reporting Person acquired beneficial ownership of shares of the Issuer's previously outstanding preferred stock in multiple separate private placements. Such preferred stock was converted into shares of Common Stock upon the closing of the Issuer's initial public offering of Common Stock (the "IPO") on October 9, 2020. The Reporting Person also previously acquired beneficial ownership of Common Stock in a private placement. ITEM 4. Purpose of transaction The shares of Common Stock held by the Reporting Person were acquired for investment purposes. Mr. Hornblower ceased to serve on the board of directors of the Issuer on October 22, 2021. The Reporting Person may from time to time hold, vote, trade, and dispose of the Common Stock of the Issuer. CUSIP No. 820824L103 13D ITEM 5. Interest in Securities of the Issuer The beneficial ownership of the Common Stock of the Issuer by the Reporting Person on the date hereof is reflected on the Cover Page above. The Reporting Person sold 534,856 shares of Common Stock of the Issuer in public market transactions, which included 70,000 shares of Common Stock beneficially owned by family members and 345,000 shares of Common Stock according to a Trading Plan under Rule 10b5-1 under the Securities Exchange Act of 1934. The shares of Common Stock were sold at an average sales price of $16.35 between May 10, 2021 and December 7, 2022. ITEM 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer The information set forth, or incorporated by reference, in Items 3 - 5 of this Statement is hereby incorporated by reference in this Items 6. The Reporting Person and certain of the Issuer's other investors were party to a Second Amended and Restated Investors' Rights Agreement, dated June 12, 2020, with the Issuer (the "Rights Agreement"). The Reporting Person entered into a lock-up agreement dated October 9, 2020, which expired as of May 9, 2021. ITEM 7. Not applicable. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. December 8, 2022 /s/ Josiah Hornblower -------------------------------- Josiah Hornblower

Get the next $STTK alert in real time by email

Date

Price Target

Rating

Analyst

10/2/2024

$8.00 → $2.00

Buy → Neutral

Citigroup

10/2/2024

Buy → Hold

Needham

10/1/2024

Buy → Neutral

H.C. Wainwright

6/17/2024

Buy → Neutral

BTIG Research

8/31/2022

$12.00

Buy

BTIG Research

6/1/2022

$13.00

Buy

Citigroup

5/2/2022

$28.00

Buy

H.C. Wainwright

SEC Form SC 13D/A filed by Shattuck Labs Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $STTK

$STTK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Shattuck Labs downgraded by Citigroup with a new price target

Shattuck Labs downgraded by Needham

Shattuck Labs downgraded by H.C. Wainwright

$STTK Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

Chief Executive Officer Schreiber Taylor bought $50,011 worth of shares (14,400 units at $3.47), increasing direct ownership by 72% to 34,502 units (SEC Form 4)

$STTK SEC Filings

Shattuck Labs Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

SEC Form 10-Q filed by Shattuck Labs Inc.

Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$STTK Market Insights

Live Market Insights

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $16

Citigroup Maintains Buy on Shattuck Labs, Lowers Price Target to $9

$STTK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Schreiber Taylor bought $44,220 worth of shares (36,500 units at $1.21), increasing direct ownership by 106% to 71,002 units (SEC Form 4)

Director Brous Tyler bought $32,768 worth of shares (8,416 units at $3.89), increasing direct ownership by 4% to 238,088 units (SEC Form 4)

Chief Executive Officer Schreiber Taylor bought $50,011 worth of shares (14,400 units at $3.47), increasing direct ownership by 72% to 34,502 units (SEC Form 4)

$STTK Financials

Live finance-specific insights

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

$STTK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

$STTK Press Releases

Fastest customizable press release news feed in the world

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

$STTK Leadership Updates

Live Leadership Updates

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

Shattuck Labs Announces Changes to its Board of Directors

Recent Analyst Ratings for
$STTK

$STTK
Analyst Ratings

$STTK
Insider Purchases

$STTK
SEC Filings

$STTK
Market Insights

$STTK
Insider Trading

$STTK
Financials

$STTK
Large Ownership Changes

$STTK
Press Releases

$STTK
Leadership Updates